source
- Alkermes reports early proof-of-concept for orexin-2 drug in ADHDAlkermes announced early-stage trial results for ALKS 7290, an orexin‑2 receptor agonist originally being developed for narcolepsy, showing proof of concept in ADHD. The study reported dose‑depend…
- Consumer groups call on FDA to strengthen generic drug testing and safety reporting under GDUFA IVConsumer health organizations used a public meeting on the reauthorization of the Generic Drug User Fee Amendments to press the FDA for more resources dedicated to testing generic medicines. The g…